Todd C. Davis - 04 Jun 2021 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: Charles S. Berkman For: Todd C. Davis
Issuer symbol
LGND
Transactions as of
04 Jun 2021
Transactions value $
$0
Form type
4
Filing time
07 Jun 2021, 21:25:22 UTC
Previous filing
14 Jun 2021
Next filing
17 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +630 +1.26% $0.00 50.8K 04 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Award $0 +3.27K $0.00 3.27K 04 Jun 2021 Common Stock 3.27K $115.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2 Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.